CollPlant Biotechnologies (NASDAQ:CLGN) Releases Quarterly Earnings Results, Misses Estimates By $0.71 EPS

Posted by Donald Scott on Mar 27th, 2026

CollPlant Biotechnologies (NASDAQ:CLGN – Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.71), FiscalAI reports. The firm had revenue of $0.06 million for the quarter, compared to the consensus estimate of $6.78 million. CollPlant Biotechnologies had a negative return on equity of 102.00% and a negative net margin of 491.31%.

CollPlant Biotechnologies Stock Performance

NASDAQ:CLGN opened at $0.66 on Friday. CollPlant Biotechnologies has a 52-week low of $0.50 and a 52-week high of $4.98. The company has a market cap of $8.45 million, a P/E ratio of -0.65 and a beta of 3.02. The stock’s 50-day simple moving average is $0.94 and its 200 day simple moving average is $1.69.

Analyst Ratings Changes

CLGN has been the subject of a number of recent research reports. D. Boral Capital downgraded CollPlant Biotechnologies from a “buy” rating to a “hold” rating in a research report on Friday, February 6th. Weiss Ratings reissued a “sell (e+)” rating on shares of CollPlant Biotechnologies in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $11.50.

Read Our Latest Research Report on CLGN

About CollPlant Biotechnologies

(Get Free Report)

CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is a regenerative medicine company that develops and commercializes recombinant human collagen (rhCollagen) and 3D bioprinting technologies for medical and aesthetic applications. The company’s proprietary plant-based rhCollagen is produced using genetically engineered tobacco plants to provide a scalable, animal-free source of human collagen that meets regulatory standards.

CollPlant’s product portfolio includes Vergenix™ wound care matrices and dermal fillers for aesthetic and reconstructive purposes, as well as a range of bioinks designed for 3D bioprinting of soft and hard tissues.